Pembrolizumab after kidney surgery for non-clear cell kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether the drug pembrolizumab, given after surgery to remove kidney cancer, can help prevent the cancer from coming back. Pembrolizumab helps your immune system fight cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have non-clear cell kidney cancer that was removed with surgery (partial or full kidney removal), and any spread was also completely removed
- You can start the study within 4 months after your surgery
- You are generally able to care for yourself (ECOG performance status 0-2)
- You have not had prior treatment for this cancer besides surgery, and no prior immunotherapy for any cancer within the last 2 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
This trial tests whether giving two immunotherapy drugs before surgery can safely shrink kidney cancer tumors and help your body fight the cancer. You would receive the drugs before your scheduled surgery, and then your cancer would be removed as planned.
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
Hear when a new Stage III Renal Cell Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.